Discovering potential drug-targets for personalized treatment of autoimmune disorders - what we learn from epidermolysis bullosa acquisita.


INTRODUCTION Epidermolysis bullosa acquisita (EBA) is a chronic autoimmune bullous dermatosis (AIBD). Treatment of EBA is challenging and mostly relies on systemic immunosuppression. During the last decade, intensive research led to the identification of new potential therapeutic targets that interfere in different phases of disease progression. Therapeutic… (More)
DOI: 10.1517/14728222.2016.1148686


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics